On 3 large California dairies, 415 lactating cows with nonsevere clinical mastitis (CM) and infected with gram-negative (GN) bacteria were randomly assigned to 1 of 3 treatment groups: nontreated control (CON; 135 cases), 2 d of ceftiofur HCl (SP2; 133 cases), or 5 d of ceftiofur HCl (SP5; 147 cases). Bacteriological cure, clinical cure, mastitis recurrence, culling or death, and overall treatment success differed among treatment groups. Although duration of milk withheld due to mastitis therapy was higher for SP5 (9.
View Article and Find Full Text PDFThe objectives of this study were to evaluate mucosal immune responses in peripartum Holstein cows, to assess the impact of intranasal modified live viral (MLV) vaccination on mucosal immunity, and to explore the relationship between genotype and peripartum immune responses. Eighty multiparous Holstein cows were randomized to receive either: 1) intranasal MLV tri-valent viral vaccine 18-24 days prior to expected calving (DC); 2) the same vaccine within twelve hours after parturition (F); 3) vaccine at both time points (DCF), or 4) no vaccine (CON). Nasal secretions and sera were collected from all cattle pre-vaccination and on multiple days before and after calving to determine concentrations of interferon beta (IFN-beta) and IFN-gamma and bovine herpesvirus-1 (BHV-1-) and bovine respiratory syncytial virus (BRSV-) specific IgA in nasal secretions, and BHV-1 and BRSV serum neutralizing (SN) titers.
View Article and Find Full Text PDF